New antibody IMT-009 tested in advanced cancers – hope for Hard-to-Treat tumors

NCT ID NCT05565417

Ongoing Disease control Sponsor: Immunitas Therapeutics Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 30 times

Summary

This early-phase trial tests a new antibody drug called IMT-009 in about 67 people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose, understand side effects, and see if the drug can shrink tumors. The study is open-label, meaning everyone knows they are getting the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Site 3000

Nashville, Tennessee, 37203, United States
Site 4060

Sarasota, Florida, 34232, United States
Site 4100

Orlando, Florida, 32827, United States
Site 4500

Oklahoma City, Oklahoma, 73104, United States
Site 5000

Denver, Colorado, 80218, United States
Site 9112

Fairfax, Virginia, 22031, United States
Site 9280

Portland, Oregon, 97239, United States
Site 9384

Austin, Texas, 78705, United States
Site 9618

Tucson, Arizona, 85711, United States

Conditions

The condition(s) this trial relates to.

Burkitt lymphoma colorectal cancer colorectal neoplasm diffuse large B-cell lymphoma esophageal cancer Esophageal Neoplasms follicular lymphoma head and neck squamous cell carcinoma Hodgkins lymphoma hormone receptor-positive breast cancer lymphoma non-small cell lung carcinoma skin squamous cell carcinoma small intestine carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BURKITT LYMPHOMA COLORECTAL CANCER CUTANEOUS SQUAMOUS CELL CARCINOMA DIFFUSE LARGE B-CELL LYMPHOMA ESOPHAGEAL CANCER FOLLICULAR LYMPHOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA HODGKIN LYMPHOMA HORMONE RECEPTOR POSITIVE BREAST CARCINOMA NON SMALL CELL LUNG CANCER NON SMALL CELL LUNG CANCER SMALL BOWEL CANCER TRIPLE NEGATIVE BREAST CANCER